Genetic Polymorphisms in FAS (CD95) and FAS Ligand (CD178) Promoters and Risk of Tobacco-related Oral Carcinoma: Gene–Gene Interactions in High-risk Indians

REFERENCES

• Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
   PubMed Web of Science ®Google Scholar
• Saranath D. Epidemiology and prevention of head and neck cancer: a global view. In Contemporary Issues in Oral Cancer. Oxford: Oxford University Press, 2000.
   Google Scholar
• Das SN, Khare P, Singh MK, Sharma SC. Fas receptor (CD95) & Fas ligand (CD178) expression in patients with tobacco-related intraoral squamous cell carcinoma. Indian J Med Res 2011;134:54–60.
   PubMed Web of Science ®Google Scholar
• Cheng J, Liu C, Koopman WJ, Mountz JD. Characterization of human Fas gene. Exon/intron organization and promoter region. J Immunol 1995;154:1239–1245.
   PubMed Web of Science ®Google Scholar
• Nagata S. Fas ligand and immune evasion. Nat Med 1996;2:1306–1307.
   PubMed Web of Science ®Google Scholar
• Suda T, Takahashi T, Golstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169–1178.
   PubMed Web of Science ®Google Scholar
• Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 1995;81:505–512.
   PubMed Web of Science ®Google Scholar
• Zhang X, Miao X, Sun T, Tan W, Qu S, Xiong P, Zhou Y, Lin D. Functional polymorphisms in cell death pathway genes FAS and FASL contribute to risk of lung cancer. J Med Genet 2005;42:479–484.
   PubMed Web of Science ®Google Scholar
• Huang QR, Morris D, Manolios N. Identification and characterization of polymorphisms in the promoter region of the human Apo-1/Fas (CD95) gene. Mol Immunol 1997;34:577–582.
   PubMed Web of Science ®Google Scholar
• Sibley K, Rollinson S, Allan JM, Smith AG, Law GR, Roddam PL, Skibola CF, Smith MT, Morgan GJ. Functional FAS promoter polymorphisms are associated with increased risk of acute myeloid leukemia. Cancer Res 2003;63:4327–4330.
   PubMed Web of Science ®Google Scholar
• Bolstad AI, Wargelius A, Nakken B, Haga HJ, Jonsson R. Fas and Fas ligand gene polymorphisms in primary Sjögren's syndrome. J Rheumatol 2000;27:2397–2405.
   PubMed Web of Science ®Google Scholar
• Wu J, Metz C, Xu X, Abe R, Gibson AW, Edberg JC, Cooke J, Xie F, Cooper GS, Kimberly RP. A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: a candidate background gene in African American systemic lupus erythematosus patients. J Immunol 2003;170:132–138.
   PubMed Web of Science ®Google Scholar
• Sun T, Miao X, Zhang X, Tan W, Xiong P, Lin D. Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1030–1036.
   PubMed Web of Science ®Google Scholar
• Ueda M, Hung Y-C, Terai Y, Yamaguchi H, Saito J, Nunobiki O, Noda S, Ueki M. Fas gene promoter −670 polymorphism (A/G) is associated with cervical carcinogenesis. Gynecol Oncol 2005;98:129–133.
   PubMed Web of Science ®Google Scholar
• Das SN, Baniasadi V, Kapuria V. Association of −308 TNF-alpha promoter polymorphism with type 1 diabetes in North Indians. Int J Immunogenet 2006;33:411–416.
   PubMed Web of Science ®Google Scholar
• Baniasadi V, Narain N, Goswami R, Das SN. Promoter region −318 C/ T and −1661 A/G CTLA-4 single nucleotide polymorphisms and type 1 diabetes in North Indians. Tissue Antigens 2006;67:383–389.
   PubMed Web of Science ®Google Scholar
• Lai H-C, Sytwu H-K, Sun C-A, Yu M-H, Yu C-P, Liu H-S, Chang C-C, Chu T-Y. Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int J Cancer 2003;103:221–225.
   PubMed Web of Science ®Google Scholar
• Sobin L, Gospodarowicz M, Wittekind C. TNM Classification of Malignant Tumors. Oxford: Wiley-Blackwell, 2009.
   Google Scholar
• Zhang Z, Shi Q, Sturgis EM, Spitz MR, Hong WK, Wei Q. Thymidylate synthase 5’- and 3’-untranslated region polymorphisms associated with risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2004; 10:7903–7910.
   PubMed Web of Science ®Google Scholar
• Loro LL, Vintermyr OK, Johannessen AC, Liavaag PG, Jonsson R. Suppression of Fas receptor and negative correlation of Fas ligand with differentiation and apoptosis in oral squamous cell carcinoma. J Oral Pathol Med 1999;28:82–87.
   PubMed Web of Science ®Google Scholar
• Shimoyama M, Kanda T, Liu L, Koyama Y, Suda T, Sakai Y, Hatakeyama K. Expression of Fas ligand is an early event in colorectal carcinogenesis. J Surg Oncol 2001;76:63–68.
   PubMed Web of Science ®Google Scholar
• Hill LL, Ouhtit A, Loughlin SM, Kripke ML, Ananthaswamy HN, Owen-Schaub LB. Fas ligand: a sensor for DNA damage critical in skin cancer etiology. Science 1999;285:898–900.
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Whiteside TL. Human circulating CD4+CD25highFoxp3 +regulatory T cells kill autologous CD8+ but not CD4+ responder cells by Fas-mediated apoptosis. J Immunol 2009;182:1469–1480.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang L-E, Sturgis EM, El-Naggar AK, Hong WK, Amos CI, Spitz MR, Wei Q. Polymorphisms of FAS and FAS ligand genes involved in the death pathway and risk and progression of squamous cell carcinoma of the head and neck. Clin Cancer Res 2006;12:5596–5602.
   PubMed Web of Science ®Google Scholar
• Krippl P, Langsenlehner U, Renner W, Köppel H, Samonigg H. Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J Natl Cancer Inst 2004;96:1478–1479.
   PubMed Web of Science ®Google Scholar
• Zhu Q, Wang T, Ren J, Hu K, Liu W, Wu G. FAS-670A/G polymorphism: a biomarker for the metastasis of nasopharyngeal carcinoma in a Chinese population. Clin Chim Acta 2010;411:179–183.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Qiu L, Wang M, Tong N, Li J, Zhang Z. The FAS ligand promoter polymorphism, rs763110 (−844C>T), contributes to cancer susceptibility: evidence from 19 case-control studies. Eur J Hum Genet 2009;17:1294–1303.
   PubMed Web of Science ®Google Scholar
• Gormus U, Ergen A, Yilmaz H, Dalan B, Berkman S, Isbir T. Fas-1377A/G and FasL-844 T/C gene polymorphisms and epithelial ovarian cancer. Anticancer Res 2007;27:991–994.
   PubMed Web of Science ®Google Scholar
• Wang L-H, Ting S-C, Chen C-H, Tsai C-C, Lung O, Liu T-C, Lee C-W, Wang Y-Y, Tsai C-L, Lin Y-C. Polymorphisms in the apoptosis-associated genes FAS and FASL and risk of oral cancer and malignant potential of oral premalignant lesions in a Taiwanese population. J Oral Pathol Med 2010;39:155–161.
   PubMed Web of Science ®Google Scholar
• Sung W-W, Wang Y-C, Cheng Y-W, Lee M-C, Yeh K-T, Wang L, Wang J, Chen C-Y, Lee H. A polymorphic −844T/C in FasL promoter predicts survival and relapse in non-small cell lung cancer. Clin Cancer Res 2011;17:5991–5999.
   PubMed Web of Science ®Google Scholar
• Müschen M, Warskulat U, Beckmann MW. Defining CD95 as a tumor suppressor gene. J Mol Med 2000;78:312–325.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Wakisaka S, Takeba Y, Mihara S, Sakane T. Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell Immunol 1999;192:48–53.
   PubMed Web of Science ®Google Scholar
• Bijl M, Horst G, Limburg PC, Kallenberg CG. Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J Clin Invest 2001;31:550–553.
   PubMed Web of Science ®Google Scholar
• Crew KD, Gammon MD, Terry MB, Zhang FF, Agarwal M, Eng SM, Sagiv SK, Teitelbaum SL, Neugut AI, Santella RM. Genetic polymorphisms in apoptosis-associated genes FAS and FASL and breast cancer risk. Carcinogenesis 2007;28:2548–2551.
   PubMed Web of Science ®Google Scholar